Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio’s approachConference call today, November 9 at 4:30 PM ET CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML).

迄今为止治疗的所有7名患者均实现了trem-cel的原发性中性粒细胞植入所有3名接受多发性Mylotarg治疗的患者™剂量表现出血液学保护作用，进一步验证了Vor Bio今天，11月9日下午4:30 ET CAMBRIDGE，Mass。，2023年11月9日（GLOBE NEWSWIRE）-Vor Bio（纳斯达克股票代码：Vor），临床阶段细胞和基因组工程公司，今天提供了VBP101治疗患者的最新临床数据，其1/2a期多中心，开放标签，trem-cel（VOR33）在急性髓性白血病（AML）患者中的首次人体研究。

Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida will present these data on November 10, 4:15PM PST, in an oral presentation at the ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²) in Los Angeles, California.

Guenther Koehne，医学博士，博士，南佛罗里达州迈阿密浸信会健康研究所血液和骨髓移植及血液肿瘤学副主任兼主任将于11月10日下午4:15在PST口头报告中介绍这些数据。ASTCT/EBMT第六届国际移植和细胞治疗复发会议（HSCT²）在加利福尼亚州洛杉矶。

“With this additional hematologic protection data in multiple patients over multiple doses of Mylotarg, we are now seeing the promise of our approach come to light as a potential next-generation therapeutic option for AML patients,” said Eyal Attar, MD, Vor Bio’s Chief Medical Officer. “Now with VCAR33ALLO in the clinic, we have the potential for an even better combination with trem-cel with the goal of providing durable responses or even a potential cure for AML.” “The results being presented further validate Vor Bio’s platform and approach.

“有了多剂量Mylotarg的多名患者的额外血液学保护数据，我们现在看到我们的方法有望成为AML患者潜在的下一代治疗选择，”Vor Bio医学博士Eyal Attar说。首席医疗官。“现在在临床上使用VCAR33ALLO，我们有可能与trem-cel进行更好的组合，目标是提供持久的反应，甚至可以治愈AML。”结果进一步验证了Vor Bio的平台和方法。

We are excited to see that trem-cel has worked as expected in these patients, providing them with hematologic protection and exposing their leukemia to targeted therapy,” said Dr. Koehne. Additional data demonstrated successful engraftment of trem-cel in all seven patients Primary neutr.

Koehne博士说，我们很高兴看到trem-cel在这些患者中按预期工作，为他们提供血液学保护并使他们的白血病接受靶向治疗。其他数据表明，在所有7名患者原发性neutr中成功植入了trem-cel。